Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07101640 · ClinicalTrials.gov registry record · Phase 1
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
A Phase 1 study of Critical Illness and Bronchopulmonary Dysplasia (BPD), sponsored by Duke University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT07101640 is a Phase 1 study of Critical Illness and Bronchopulmonary Dysplasia (BPD) that is actively recruiting participants, run by Duke University. The registered enrollment target is 28 participants, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07101640, a Phase 1 study of Critical Illness and Bronchopulmonary Dysplasia (BPD), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to learn how safe montelukast may be in premature infants at significant risk for Bronchopulmonary Dysplasia (BPD) and to determine how much and how quickly montelukast moves from the stomach into the bloodstream, and how quickly it is removed from the bloodstream. Data supporting the prospect of montelukast benefit involved 6 previous studies involving 206 preterm infants. The dosing ranged from 0.5 to 2.5 mg/kg/day, which aligns with the proposed initial dose of 0.75 mg/kg/day. Though each previous study had a small population, collectively they reveal montelukast as a promising drug in populations of preterm infants developing BPD and for individual preterm infants who are "developing BPD." Thus, researchers expect clinical benefit for preterm infants in this study. Despite the benefit-to-risk ratio presented by these previous studies, the optimal dose remains to be determined; thus, this study design and PK analysis will start with the lowest dose that is likely to provide direct benefit to participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG montelukast 4 mg granule
Study Locations (4)
North Carolina
- University of North Carolina (UNC) - Chapel Hill
- East Carolina University - Greenville
Arkansas
- Arkansas Children's Hospital - Little Rock
Nevada
- University Medical Center of Southern Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07101640
The ClinicalTrials.gov registry entry for NCT07101640 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (99% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Critical Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07101640 reports 4 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Arkansas, Nevada.
Frequently Asked Questions
What is clinical trial NCT07101640 about?
NCT07101640 is a clinical study titled "PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia". The purpose of the study is to learn how safe montelukast may be in premature infants at significant risk for Bronchopulmonary Dysplasia (BPD) and to determine how much and how quickly montelukast moves from the stomach into the bloodstream, and how quickly it is removed from the bloodstream. Data ...
What is the current status of trial NCT07101640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-02-23. Estimated completion is 2028-05-31.
What conditions does trial NCT07101640 study?
This clinical trial studies the following conditions: Critical Illness, Bronchopulmonary Dysplasia (BPD), Premature Births.
What interventions are being tested in trial NCT07101640?
The interventions under investigation include: Placebo (DRUG), montelukast 4 mg granule (DRUG).
Who is sponsoring clinical trial NCT07101640?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07101640 being conducted?
This trial has 4 study locations across Arkansas, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial
RECRUITING · Phase 1
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Improving Needs Among Older Adults
RECRUITING · NA
-
The Family Perspectives Project Pilot Trial
RECRUITING · NA
-
12-hour Time Limited Feeding in Critical Care
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.